efficacy

2:53
Effect of FGFR status on checkpoint inhibitor response in bladder cancer
Tracy Rose
4:10
Non-clear cell kidney cancer trial updates: CALYPSO and KEYNOTE-427
Tracy Rose
2:46
IO-IO vs. IO-VEGF inhibitor therapy for mRCC
Shaan Dudani
1:26
SPIRE trial: overcoming cisplatin resistance in bladder cancer with transcriptome changes
Simon Crabb
1:46
New promise in treating mBC: combining anti-AR therapy with chemotherapy
Shilpa Gupta
2:20
ProCAID: Investigating the use of AZD5363 alongside chemotherapy in mCRPC
Simon Crabb
2:40
Key prostate cancer news from GU 2019
Simon Crabb
2:05
Immunotherapy resistance mechanisms and predicting NMIBC patient immune responses.
Randy Sweis
2:29
Bladder cancer treatment updates by Prof. Jones
Robert Jones
1:25
Progress and challenges of immunotherapy for bladder cancer
Randy Sweis
2:07
Key updates on testicular cancer management
Robert Huddart
4:13
Using the urinary microbiome to predict BCG therapy responses in bladder cancer patients.
Randy Sweis
5:30
Zuclomiphene citrate: overcoming the estrogenic side effects of ADT in mCRPC patients
Robert Getzenberg
4:10
Combination of minimally invasive surgery and carboplatin for stage IIa seminoma
Robert Huddart
1:02
Non-clear cell sarcamatoid kidney cancer treatment updates
Rana McKay
3:35
Prof. Jones’ updates on prostate cancer treatments
Robert Jones
vjoncology logo VJOncology is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

VJO needs the contact information you provide to inform you about our latest oncology news and videos, educational courses and industry supported content (some of which may be promotional in nature). You may unsubscribe from these communications at anytime. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy.

The content of VJOncology is intended for healthcare professionals